Endocarditis Caused byStaphylococcus aureuswith Reduced Susceptibility to Vancomycin | Zendy

Christopher W. Woods | Zendy; Allen C. Cheng | Zendy; Vance G. Fowler | Zendy; Mary Moorefield | Zendy; Joyce Frederick | Zendy; George Sakoulas | Zendy; Venkata G. Meka | Zendy; Fred C. Tenover | Zendy; Peter Zwadyk | Zendy; Kenneth H. Wilson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Endocarditis Caused byStaphylococcus aureuswith Reduced Susceptibility to Vancomycin

Author(s) -

Christopher W. Woods,

Allen C. Cheng,

Vance G. Fowler,

Mary Moorefield,

Joyce Frederick,

George Sakoulas,

Venkata G. Meka,

Fred C. Tenover,

Peter Zwadyk,

Kenneth H. Wilson

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/383027

Subject(s) - vancomycin , medicine , staphylococcus aureus , infective endocarditis , endocarditis , microbiology and biotechnology , staphylococcal infections , antibiotics , micrococcaceae , methicillin resistant staphylococcus aureus , antibacterial agent , bacteria , biology , genetics

Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research